Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04234113 · ClinicalTrials.gov registry record · Phase 1
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by SOTIO Biotech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT04234113 is a Phase 1 study that was terminated before completion, run by SOTIO Biotech. The registered enrollment target is 115 participants.
The verdict
NCT04234113, a Phase 1 study, was terminated before completion, sponsored by SOTIO Biotech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Interventions
- DRUG Pembrolizumab
- DRUG Nanrilkefusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04234113
The ClinicalTrials.gov registry entry for NCT04234113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SOTIO Biotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04234113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04234113 about?
NCT04234113 is a clinical study titled "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors". A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
What is the current status of trial NCT04234113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2019-06-13. Estimated completion is 2024-11-27.
What interventions are being tested in trial NCT04234113?
The interventions under investigation include: Pembrolizumab (DRUG), Nanrilkefusp alfa (DRUG).
Who is sponsoring clinical trial NCT04234113?
This trial is sponsored by SOTIO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.